Remimazolam as a Primary Agent for Brief Invasive and Noninvasive Procedures: A Case Series

Remimazolam is a novel benzodiazepine with sedative and amnestic properties similar to midazolam. Ester metabolism results in a half-life of 5 -10 min and a limited context sensitive half-life. We present preliminary retrospective experience with its use as a primary agent for procedural sedation for brief invasive and noninvasive procedures. The study cohort included seven patients, ranging in age from 14 to 51 years. Remimazolam administration included bolus dosing in two pa-tients and a combination of bolus dosing followed by an infusion in the other five patients. The initial bolus dose of remimazolam ranged from 2.5 to 5 mg. Starting doses for the infusion ranged from 10 to 30 mu g/ kg/min with titration of the continuous infusion during the procedure, ranging from 10 -30 mu g/kg/min. Median dose infusion requirements were 15 -20 mu g/kg/min. One procedure was completed with remimazolam as the sole anesthetic agent while the other six patients received adjunctive agents. Changes in blood pressure or oxygen saturation were noted which resolved with minimal interventions such as a decrease in remimazolam infusion rate or an increase in supplemental oxygen ad-ministration. Our anecdotal experience provides further support for the efficacy of remimazolam as an agent for procedural sedation.